PE20021101A1 - Derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos - Google Patents

Derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos

Info

Publication number
PE20021101A1
PE20021101A1 PE2002000242A PE2002000242A PE20021101A1 PE 20021101 A1 PE20021101 A1 PE 20021101A1 PE 2002000242 A PE2002000242 A PE 2002000242A PE 2002000242 A PE2002000242 A PE 2002000242A PE 20021101 A1 PE20021101 A1 PE 20021101A1
Authority
PE
Peru
Prior art keywords
triona
derivatives
pirimidin
procedure
production
Prior art date
Application number
PE2002000242A
Other languages
English (en)
Inventor
Gagmar Geppert
Frank Grams
Gerd Zimmermann
Herbert Leinert
Ernesto Menta
Hans-Willi Krell
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20021101A1 publication Critical patent/PE20021101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIMIDIN-2,4,6-TRIONA DE FORMULA I DONDE R1 ES FENILO, FENOXILO, FENILTIO, FENILSULFINILO, FENILAMINO, ENTRE OTROS; R2 ES H; R3 ES H, ALQUILO, ENTRE OTROS; R4 ES ALQUILO, ENTRE OTROS; R2, R3 Y R4 JUNTO A N FORMAN UN ANILLO DE PIPERAZINA. SON COMPUESTOS PREFERIDOS 5-[4-(4-CLORO-FENOXI)-FENIL]-5-[4-(2,3-DIHIDROXI-PROPIL)-PIPERACIN-1-IL]-PIRIMIDIN-2,4,6-TRIONA, 5-[4-(4-CLORO-FENOXI)-FENIL]-5-[4-[2-(2-DIHIDROXI-ETOXI)-ETIL]-PIPERACIN-1-IL]-PIRIMIDIN-2,4,6-TRIONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA METALOPROTEINASA Y SON UTILES COMO AGENTES ANTITUMORALES
PE2002000242A 2001-03-30 2002-03-26 Derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos PE20021101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01107714 2001-03-30

Publications (1)

Publication Number Publication Date
PE20021101A1 true PE20021101A1 (es) 2003-02-13

Family

ID=8176973

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000242A PE20021101A1 (es) 2001-03-30 2002-03-26 Derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos

Country Status (15)

Country Link
US (1) US6716845B2 (es)
EP (1) EP1383746A2 (es)
JP (1) JP2004533425A (es)
KR (1) KR20030086335A (es)
CN (1) CN1273454C (es)
AR (1) AR035800A1 (es)
AU (1) AU2002302470C1 (es)
BR (1) BR0208440A (es)
CA (1) CA2442354A1 (es)
MX (1) MXPA03008588A (es)
PA (1) PA8542001A1 (es)
PE (1) PE20021101A1 (es)
UY (1) UY27239A1 (es)
WO (1) WO2002079170A2 (es)
ZA (1) ZA200306615B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8726714D0 (en) 1987-11-14 1987-12-16 Beecham Group Plc Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
DK0489579T3 (da) 1990-12-03 1995-06-12 Celltech Therapeutics Ltd Peptidylderivater
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
AU725831C (en) 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19726427A1 (de) * 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
PE20010659A1 (es) 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas

Also Published As

Publication number Publication date
AR035800A1 (es) 2004-07-14
CN1273454C (zh) 2006-09-06
JP2004533425A (ja) 2004-11-04
CA2442354A1 (en) 2002-10-10
US20020187991A1 (en) 2002-12-12
UY27239A1 (es) 2002-09-30
AU2002302470C1 (en) 2008-07-24
CN1553901A (zh) 2004-12-08
WO2002079170A3 (en) 2003-11-27
AU2002302470B2 (en) 2008-02-14
ZA200306615B (en) 2004-11-25
US6716845B2 (en) 2004-04-06
BR0208440A (pt) 2004-03-30
KR20030086335A (ko) 2003-11-07
MXPA03008588A (es) 2003-12-08
WO2002079170A2 (en) 2002-10-10
PA8542001A1 (es) 2002-10-28
EP1383746A2 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
CY1108744T1 (el) 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20010683A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
PE20040892A1 (es) Antagonistas del receptor muscarinico m3 de acetilcolina
ECSP088550A (es) Nuevos compuestos que son inhibidores de erk
NI200600257A (es) Nuevos compuestos.
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20120814A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
AR049110A1 (es) Compuestos terapeuticos: piridina como andamiaje estructural
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
ECSP099781A (es) Novedosos compuestos que son inhibidores de erk
EA200300619A1 (ru) Серотонинергические средства
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
AR015712A1 (es) Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.

Legal Events

Date Code Title Description
FD Application declared void or lapsed